F
Francisco Marín
Researcher at University of Murcia
Publications - 503
Citations - 13444
Francisco Marín is an academic researcher from University of Murcia. The author has contributed to research in topics: Atrial fibrillation & Medicine. The author has an hindex of 53, co-authored 439 publications receiving 11660 citations. Previous affiliations of Francisco Marín include Carlos III Health Institute & Services Hospital.
Papers
More filters
Journal ArticleDOI
Predictive value of the CHA2DS2-VASc score in atrial fibrillation patients at high risk for stroke despite oral anticoagulation.
Eva Jover,Vanessa Roldán,Pilar Gallego,Diana Hernández-Romero,Mariano Valdés,Vicente Vicente,Gregory Y.H. Lip,Francisco Marín,Francisco Marín +8 more
TL;DR: Among high risk atrial fibrillation patients on oral anticoagulation, CHA 2 DS 2 -VASc successfully predicts cardiovascular events and mortality, but not major bleeds.
Journal ArticleDOI
Invasive Versus Conservative Strategy in Frail Patients With NSTEMI: The MOSCA-FRAIL Clinical Trial Study Design.
Juan Sanchis,Albert Ariza-Solé,Emad Abu-Assi,Oriol Alegre,Fernando Alfonso,José A. Barrabés,José Antonio Baz,Antonio Carol,Pablo Díez Villanueva,Bruno García del Blanco,Jaime Elízaga,Eduard Fernandez,Abel García del Egido,Joan García Picard,Ivan Gomez Blazquez,Rosana Hernández-Antolín,Cinta Llibre,Francisco Marín,David Martí Sánchez,Roberto Martín,Manuel Martínez Sellés,Gema Miñana,María José Morales Gallardo,Julio Núñez,Armando Pérez de Prado,Eduardo Pinar,Marcelo Sanmartín,Alessandro Sionis,Adolfo Villa,Jaume Marrugat,Héctor Bueno +30 more
TL;DR: The hypothesis is that an invasive strategy will improve prognosis in elderly frail patients with NSTEMI and if this is confirmed, frailty status should not dissuade physicians from implementing an invasive management strategy.
Journal ArticleDOI
New Perspectives in Antiplatelet Therapy
Antonio Tello-Montoliu,Eva Jover,José Rivera,Mariano Valdés,Dominick J. Angiolillo,Francisco Marín +5 more
TL;DR: The substantial progress in understating the regulation of platelet activation has played a key role in the development of novel antiplatelet agents and current clinical evaluation of these novel anti platelet agents are summarized.
Journal ArticleDOI
Prognostic role of MIR146A polymorphisms for cardiovascular events in atrial fibrillation
Vanessa Roldán,Ana B. Arroyo,Salam Salloum-Asfar,Sergio Manzano-Fernández,Nuria García-Barberá,Francisco Marín,Vicente Vicente,Rocío González-Conejero,Constantino Martínez +8 more
TL;DR: The study established MIR146A rs2431697 as a prognostic biomarker for ACE in anticoagulated AF patients and established that TT individuals, when submitted to an inflammatory stress, may be prone to a highest pro-inflammatory state due, in part, to lower levels of miR-146a-5p.
Journal ArticleDOI
β-Trace Protein: From GFR Marker to Cardiovascular Risk Predictor
Esteban Orenes-Piñero,Sergio Manzano-Fernández,Ángel López-Cuenca,Francisco Marín,Mariano Valdés,James L. Januzzi +5 more
TL;DR: Beyond its role for estimating renal function, β-trace protein is also emerging as a novel biomarker in cardiovascular risk, playing a potential role for prognostic stratification in patients with acutely decompensated heart failure and acute coronary syndromes and being advocated as a Novel marker for cardiovascular risk prediction.